Member Info for Soupdragon78

"The tranilast inhalation can effectively inhibit acute pulmonary inflammation in rats. This inhaled form can be considered as a candidate to control the pulmonary inflammation in COVID-19 patients due to its higher solubility and the need for lower drug concentrations [111,112]."

Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19

"Therefore, Tranilast may be considered as a potential treatment for patients with the acute form of COVID-19 along with other drugs."

"According to many findings associated with Tranilast, this drug that has been prescribed for many years can help in controlling inflammation, which even act as an effective antichemotactic factor, thereby resulting in an improvement in severe COVID-19 by preventing key inflammatory transcription factors like NF-?B and inhibiting NLRP-3 inflammasome. Some studies have further demonstrated the direct effect of this drug on the prevention of inappropriate tissue remodeling, which is one of the pathological events of this disease. The inhibitions of neutrophils, IL-5, and subsequently eosinophils can accordingly make Tranilast an effective drug in the regimen of patients with severe diseases. Numerous studies have comparably documented the effective role of Tranilast on the inhibition of the infiltration of inflammatory cells into the inflammation site. On the other hand, this drug along with other medications can be considered as a potential treatment for patients affected with a severe kind of COVID-19, because it inhibits factors involved in acute airway inflammation such as IL-33 and cytokine, which greatly multiply mucosal secretions like IL-13."

I live in the hope that they might one day attract someone with some spare cash to pick up 3 or 4% of the company.

Would be good if the interims were strongly supported by a good Allenby note and an attempt to build larger investor support.

Just find it interesting that’s all Older. After all the company pays Walbrook to look after their company LinkedIn profile.

Older, ok so I was a bit heavy on the superlatives.

AB’s post is relevant as it is a congrats to the company she is moving to, which she liked the day before she announced her resignation.

Whilst not a flood of posting from all of them, Maddy is the most prolific. But the principle still stands, none of them has posted/liked/shared or comments on anything about NfX at all.

Brindley even posted about the company she's moving to, but nothing on the company she's been CEO of for the past year.

Simple answer is I dunno.

Not really about secrecy, they could just click the share button on the posts on the NFX linkedin profile that have the recent news. They don't even do that.

FX, one thing I've noticed that I find odd is that all of the board members, Riddell, Brindley, Gilbert and Kennedy regularly post news on their linkedin pages, but... none of them has ever posted anything about Nuformix, lots about the other companies they work for, but not NFX?

Agree older, they previously stated they'd be getting someone external to do the business development from this point on. As they say, at that point in time they plan to start business development.

We won't know when they do, until they've finished. No bad thing.

Older, agree that NXP004 is a good short term target.

But where did you get info that discussions are currently underway?

It can be read in either direction FX. Its quite a clear statement of intent across the board that they won't talk about anything till its confirmed. This included NXP001 etc.
This was the approach outlined from day 1 by AB, she was quite clear her approach was data driven business development rather than speculative updating.

FX, they said they 'will only publicly comment on deals once they are fully signed and delivered'.

Which answers your question as to why would they not say if something only hinged on data. They won't say anything till fully sorted.
So its quite binary, either there are no talks so nothing to say, or there are talks, but they won't say anything till signed on the dotted line.

Interesting FX. Only the other day I was chuckling at the TSX interim filing for Kelly Ventures which Ebers are supposedly reversing into.
Its still ongoing as Ebers have still not issued their accounts for the past two years so cannot complete the RTO. Furthermore the report notes that Kelly Ventures will not be a going concern in the near future which could scupper the whole thing.

Good old Dave and Pascal, working their magic.

keep your erotic fantasies to yourself aj.

Some form of talks or contact will be initiated in the coming period I believe (say Q1 2022), dunno with who or to what level, but I would expect some sort of feelers to be out there.
We will hear how they plan the next year to take to clinic, but that doesn't stop any business development.

Random, DG had left before that statement, it was written by Blackwell.

FX, the companies strategy has been to undertake the inhaler work before business development.

FX, I'm saying that having more data and evidence that the drug works adds intrinsic value.

You say they have re-established contact, where did you see that?

Thanks Kane

FX, it was more the global lockdown that restricted / closed off previous discussions. Then Anne came on board and the focus has been on proving up the inhaler route, adding value to the proposition.

“ The Group previously announced that negotiations for out-licensing commercial rights for Asia markets were underway. Discussions have continued but the pace of negotiations has been limited as a result of the COVID-19 pandemic situation, closures to key sites in Asia and access to key personnel. When normal trading conditions return, with direct access to key personnel, we hope to continue these and other efforts to derive value from this product for all key world markets. The value of NXP-002 is not just confined to Asia and we intend to assess interest in regions outside Asia with additional parties.”